tiprankstipranks
Revolution Medicines reports Q3 EPS (94c), consensus (89c)
PremiumThe FlyRevolution Medicines reports Q3 EPS (94c), consensus (89c)
16d ago
Revolution Medicines price target raised to $62 from $56 at H.C. Wainwright
Premium
The Fly
Revolution Medicines price target raised to $62 from $56 at H.C. Wainwright
19d ago
Revolution Medicines price target raised to $82 from $72 at Guggenheim
Premium
The Fly
Revolution Medicines price target raised to $82 from $72 at Guggenheim
26d ago
Revolution Medicines: 1st patient dosed in RMC-6236 study for PDAC treatment
PremiumThe FlyRevolution Medicines: 1st patient dosed in RMC-6236 study for PDAC treatment
1M ago
Revolution Medicines price target raised to $60 from $54 at Barclays
Premium
The Fly
Revolution Medicines price target raised to $60 from $54 at Barclays
2M ago
Revolution Medicines participates in a conference call with JPMorgan
Premium
The Fly
Revolution Medicines participates in a conference call with JPMorgan
2M ago
Revolution Medicines reiterates 2024 GAAP net loss guidance
PremiumThe FlyRevolution Medicines reiterates 2024 GAAP net loss guidance
4M ago
Revolution Medicines reports Q2 EPS (81c), consensus (77c)
Premium
The Fly
Revolution Medicines reports Q2 EPS (81c), consensus (77c)
4M ago
Revolution Medicines price target raised to $54 from $52 at Barclays
Premium
The Fly
Revolution Medicines price target raised to $54 from $52 at Barclays
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100